GlassScriptPhysician profile
Steven Joel King
NPI 1629069083
$1,440.15
in general payments reported to CMS, 2019-2025
25 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $161 · 2023: $332 · 2024: $384 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $184.18 | 2023-2025 | |
| Abbvie INC. | $164.74 | 2021-2025 | |
| Novo Nordisk INC | $130.90 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $102.07 | 2023-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $93.66 | 2021-2024 | Spravato |
| Lilly USA, LLC | $87.81 | 2021-2024 | Mounjaro, Jardiance |
| Biohaven Pharmaceuticals, INC. | $77.85 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $69.09 | 2025 | Ajovy |
| Exact Sciences Corporation | $68.87 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $59.73 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $57.42 | 2021-2023 | Proclaim |
| Hologic Sales and Service, LLC | $40.89 | 2022-2024 | Aptima |
| Optinose US, INC. | $39.15 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.46 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $33.01 | 2023 | Nuedexta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $31.47 | 2022 | |
| Glaxosmithkline, LLC. | $24.07 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Phadia US INC. | $21.62 | 2024 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.96 | 2025 | Caplyta |
| Shield Therapeutics INC | $19.95 | 2023 | Accrufer |
| Sanofi-Aventis U.S. LLC | $19.69 | 2024 | |
| Impulse Dynamics (USA) INC. | $15.83 | 2024 | Optimizer |
| Corcept Therapeutics | $15.54 | 2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.94 | 2025 | Jardiance |
| Boston Scientific Corporation | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.